Clinical Trial

Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease

Study acronym: UPSTREAM SjD
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease (UPSTREAM SjD)
Protocol Amendment History 7 changes
notable Trial sites expanded: 28 -> 38 locations 2026-08-11
notable Trial sites expanded: 18 -> 24 locations 2026-05-20
notable Trial sites expanded: 12 -> 18 locations 2026-05-06
notable Trial sites expanded: 8 -> 12 locations 2026-04-30
notable Trial sites expanded: 5 -> 8 locations 2026-04-21
notable Primary completion pushed: 2028-06 -> 2028-12 2026-04-03
minor Completion pushed: 2028-08 -> 2029-01 2026-04-03
Trial Details
NCT Number NCT07404865
Lead Sponsor Vor Biopharma
Conditions Primary Sjogren's Disease
Enrollment 250 participants
Start Date 2026-02-26
Primary Completion 2028-12 (estimated)
Study Completion 2029-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-10